Medical News

RSS

Lexicon initiates Phase 2 clinical trial of LX4211 in patients with type 2 diabetes mellitus

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained favorable results from recently completed Phase 1 studies of LX4211 and announced today that it has initiated a Phase 2 clinical trial of the drug candidate in patients with type 2 diabetes mellitus.

15 Sep 2009

Texas Cardiac Arrhythmia Institute to utilize Odyssey systems

Stereotaxis, Inc., announced that the Texas Cardiac Arrhythmia Institute at St. David's Medical Center in Austin, Texas ordered four Odyssey(TM) systems.

15 Sep 2009

1-800-DENTIST re-launches its popular dental blog

1-800-DENTIST®, the nation's leading free resource for consumers in search of a dentist, is re-launching its popular dental blog, DentistLove.com. The revamped site offers more features and bloggers, adding a variety of 1-800-DENTIST® employees blogging about their own unique stories regarding dentistry and oral hygiene.

15 Sep 2009

HealthInsight unveils value-based solutions to reduce health care costs

HealthInsight, provider of the only value-based health care administration platform, officially unveils a set of technology and services for health insurers, third-party administrators and employers that are proven to lower overall medical costs while improving the quality of care. The new platform will be used to determine and track health actions that are directly tied to benefit designs, which is instrumental in lowering health care costs.

15 Sep 2009

HemCon Medical Technologies and Zimmer Dental sign distribution agreement

HemCon Medical Technologies, Inc. (“HemCon”), a leading developer of advanced medical products, is proud to announce the signing of an exclusive global distribution agreement with Zimmer Dental Inc., a leading provider of dental oral rehabilitation products and a subsidiary of Zimmer Holdings, Inc.

15 Sep 2009

Chief of Robotics and Minimally Invasive Surgery shares views on medical tourism

In light of the economy and rising unemployment, people are looking to cut costs wherever they can. As the costs of many surgeries and procedures continue to rise in the US, many are looking for cheaper alternatives abroad. This big business is known as "medical tourism," and often promises healthcare options at a fraction of the cost as in the United States. However, this is one area where bargain shopping is not recommended, counsels Dr. David B. Samadi, Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York City.

15 Sep 2009

First edition: September 15, 2009

Today's headlines zero in on the soon-to-be unveiled Baucus health bill. Reports indicate it likely will address many GOP concerns but also raising new issues for some Democrats.

15 Sep 2009

New program educates parents on fun, healthy mealtime ideas

How did the simple act of eating become so difficult? Between basic nutrition, the obesity epidemic, allergies, food recalls, and chemical contaminants, feeding children a healthy diet has never been so complicated. Eat Healthy, a new program from Healthy Child Healthy World, makes it easy.

15 Sep 2009

National Community Pharmacists Association calls for suspension of the DMEPOS accreditation requirement

The National Community Pharmacists Association (NCPA), has written a letter to Charlene Frizzera, Centers for Medicare and Medicaid Services (CMS) Acting Administrator, urging a suspension of the Medicare Part B Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) accreditation requirement scheduled for October 1.

15 Sep 2009

GlaxoSmithKline's Votrient will take significant market share away from Pfizer's Sutent by 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.

15 Sep 2009

IMPROVE HF clinical trial results presented at annual HFSA meeting

Twenty-four month findings from IMPROVE HF, (The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting), funded by Medtronic, Inc., demonstrated that clinics using the process improvement program increased adherence to evidence-based, guideline-recommended care by 82 and 62 percent, respectively, for cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillator (ICD) use, and 80 percent for aldosterone antagonist use, all relative to baseline results.

15 Sep 2009

Sentinel Cardiology Information Management Systems from Spacelabs Healthcare

Spacelabs Healthcare is pleased to announce the U.S. launch of Sentinel, a sophisticated Cardiology Information Management Systems (CIMS), that will facilitate analysis and reporting while also improving efficiency and eliminating errors.

15 Sep 2009

"High Five" factors in overweight men impacts their energy and health: Building Healthier America

For overweight men ages 45 and older, the "High Five" factors of high cholesterol, high blood pressure, high blood sugar/glucose, poor diet and low testosterone may be impacting their energy and health, sabotaging efforts to lose weight, according to Building Healthier America, a national nonprofit organization dedicated to reversing the negative trends of overweight and obesity in the U.S.

15 Sep 2009

KYTHERA initiates proof-of-concept trial of its ATX-104 light-activated facial contouring agent

KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced that it has initiated a first-in-human, proof-of-concept study evaluating the safety, tolerability, persistence and histological effects of ATX-104, a light-activated facial contouring agent.

15 Sep 2009

Stevens receives training grant from LWD

Stevens Institute of Technology has again been awarded a $563,600 High-Growth Workforce Development training grant from the New Jersey Department of Labor and Workforce Development (LWD).

15 Sep 2009

NCF aims to improve cancer care by providing easily accessible tools

The NavigateCancer Foundation (NCF), a nonprofit staffed by oncology professionals, provides patient advocacy tools and services for cancer patients and families, is filling an especially vital role as the ranks of the unemployed and uninsured steadily swell.

15 Sep 2009

Cytheris' INSPIRE study data of HIV-infected patients with low CD4 T cell counts announced

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced presentation of data from an interim analysis of CLI-107-06 (INSPIRE), a Phase I/IIa study of HIV-infected patients with low CD4 T cell counts. The patients were treated with a three-injection cycle of the Company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107).

15 Sep 2009

A.P. Pharma and Merial sign license and development agreement for a long-acting pain management product

A.P. Pharma (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it has entered into a license and development agreement with Merial, a world leading animal health company, for a long-acting pain management product.

15 Sep 2009

FluCide more effective than Tamiflu

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Anil Diwan, PhD, President of the Company presented a talk at NanoBusiness 2009 - the 8th annual NanoBusiness Conference in Chicago, IL, on Wednesday, September 9th.

15 Sep 2009

Researchers use mTeSR1 medium for deriving human induced pluripotent stem cells

In a landmark paper, researchers at Stanford University have described a new way to derive human induced pluripotent stem cells (iPSCs) without the use of contaminating mouse feeder cells. Using adipose cells as the starting cell population and mTeSR™1, a defined medium that allows the expansion of human embryonic and induced pluripotent stem cells without the use of feeders, the researchers were able to fully reprogram the cells to the pluripotent state.

15 Sep 2009

Medical News

Lexicon initiates Phase 2 clinical trial of LX4211 in patients with type 2 diabetes mellitus

Texas Cardiac Arrhythmia Institute to utilize Odyssey systems

1-800-DENTIST re-launches its popular dental blog

HealthInsight unveils value-based solutions to reduce health care costs

HemCon Medical Technologies and Zimmer Dental sign distribution agreement

Chief of Robotics and Minimally Invasive Surgery shares views on medical tourism

First edition: September 15, 2009

New program educates parents on fun, healthy mealtime ideas

National Community Pharmacists Association calls for suspension of the DMEPOS accreditation requirement

GlaxoSmithKline's Votrient will take significant market share away from Pfizer's Sutent by 2018

IMPROVE HF clinical trial results presented at annual HFSA meeting

Sentinel Cardiology Information Management Systems from Spacelabs Healthcare

"High Five" factors in overweight men impacts their energy and health: Building Healthier America

KYTHERA initiates proof-of-concept trial of its ATX-104 light-activated facial contouring agent

Stevens receives training grant from LWD

NCF aims to improve cancer care by providing easily accessible tools

Cytheris' INSPIRE study data of HIV-infected patients with low CD4 T cell counts announced

A.P. Pharma and Merial sign license and development agreement for a long-acting pain management product

FluCide more effective than Tamiflu

Researchers use mTeSR1 medium for deriving human induced pluripotent stem cells

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Latest News